Acalabrutinib Suppliers & Bulk Manufacturers
Available Forms: Oral Capsules
Available Strengths: 100 mg
Reference Brands: Calquence® (EU & US)
Category:
Oncology Cancer Care
Acalabrutinib Capsules (brand name Calquence®) are used to treat CLL and MCL, targeting BTK to block malignant B-cell growth. Available in 100 mg strength, they are manufactured under GMP standards and approved in both US and EU markets as a reliable oncology therapy.
Acalabrutinib is available in Oral Capsules
and strengths such as 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Acalabrutinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Acalabrutinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Acalabrutinib Capsules are a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By targeting and inhibiting BTK, Acalabrutinib prevents the survival and proliferation of malignant B-cells. Marketed under the brand name Calquence®, Acalabrutinib offers an effective solution for patients who have not responded to other treatments or as a first-line therapy. Available in a 100 mg oral capsule strength, Acalabrutinib is manufactured under GMP-compliant conditions, providing a reliable oncology treatment for US and EU markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing